Celularity (CELU) Stock Price, News & Analysis

Company Overview

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Key Stats

• Today's Range: $3.61 to $3.98
• 50-Day Range: $1.74 to $4.15
• 52-Week Range: $1.00 to $5.22
• Volume: 48,756 shs
• Average Volume: 169,381 shs
• Market Capitalization: $90.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: N/A

Celularity Stock Analysis - MarketRank™

Celularity scored higher than 15% of companies evaluated by MarketBeat, and ranked 883rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: N/A

Amount of Analyst Coverage

Celularity has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Celularity is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Celularity is -1.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Celularity has a P/B Ratio of 10.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.50% of the float of Celularity has been sold short.

Short Interest Ratio / Days to Cover

Celularity has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Celularity has recently increased by 8.39%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Celularity does not currently pay a dividend.

Dividend Growth

Celularity does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.50% of the float of Celularity has been sold short.

Short Interest Ratio / Days to Cover

Celularity has a short interest ratio ("days to cover") of 7.

Change versus previous month

Short interest in Celularity has recently increased by 8.39%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.9 / 5
• News Sentiment: 0.42

News Sentiment

Celularity has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Celularity this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for CELU on MarketBeat in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Celularity insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.10% of the stock of Celularity is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 19.02% of the stock of Celularity is held by institutions.

CELU Stock Analysis - Frequently Asked Questions

How have CELU shares performed this year?

Celularity's stock was trading at $2.08 on January 1st, 2025. Since then, CELU shares have increased by 81.0% and is now trading at $3.7650.

How were Celularity's earnings last quarter?

Celularity, Inc. (NASDAQ:CELU) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.59) earnings per share for the quarter, beating analysts' consensus estimates of ($1.50) by $0.91. The firm earned $18.13 million during the quarter, compared to the consensus estimate of $5.20 million. Celularity had a negative trailing twelve-month return on equity of 271.88% and a negative net margin of 106.77%.

When did Celularity's stock split?

Shares of Celularity reverse split before market open on Thursday, February 29th 2024.The 1-10 reverse split was announced on Thursday, February 29th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 29th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Who are Celularity's major shareholders?

Celularity's top institutional investors include Valmark Advisers Inc. (0.21%), Bank of America Corp DE (0.16%), XTX Topco Ltd (0.09%) and Simplex Trading LLC. Insiders that own company stock include Kok Thay Lim and Robert J Hariri.
View institutional ownership trends.

How do I buy shares of Celularity?

Shares of CELU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Celularity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Celularity investors own include NVIDIA (NVDA), Meta Platforms (META), Lovesac (LOVE), MannKind (MNKD), PayPal (PYPL), Tesla (TSLA) and Advanced Micro Devices (AMD).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 8/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CELU
• CIK: 1752828
• Web: www.celularity.com
• Phone: 908-768-2170
• Fax: N/A
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Celularity: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +58.9%
• Consensus Rating: N/A
• Rating Score (0-4): 0.00
• Research Coverage: 0 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.65)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$57.89 million
• Net Margins: -106.77%
• Pretax Margin: -106.77%
• Return on Equity: -271.88%
• Return on Assets: -42.82%

Debt

• Debt-to-Equity Ratio: 4.07
• Current Ratio: 0.38
• Quick Ratio: 0.28

Sales & Book Value

• Annual Sales: $54.22 million
• Price / Sales: 1.67
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.37 per share
• Price / Book: 10.20

Miscellaneous

• Outstanding Shares: 23,950,000
• Free Float: 18,656,000
• Market Cap: $90.41 million
• Optionable: Optionable
• Beta: 0.79